Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus and comparison of hypoglycemic action of concomitant medications: a subanalysis of the JAMP study
Noriko Ujihara,Hiroshi Sakura,Naotake Hashimoto,Kazuo Sasamoto,Hiroshi Ohashi,Sumiko Hasumi,Tadasu Kasahara,Osamu Tomonaga,Hideo Nunome,Masashi Honda,Yasuhiko Iwamoto,JAMP Study Investigators,Akiko Sato,Akira Miyashita,Asako Kokubo,Atsuro Tsuchiya,Dai Hirohara,Daiji Kogure,Daijo Kasahara,Hideki Tanaka,Hideo Tezuka,Hiroyuki Kuroki,Jun Ogino,Kanu Kin,Kazuko Muto,Kazuo Suzuki,Keiko Iseki,Keita Watanabe,Kenshi Higami,Kenzo Matsumura,Kiyotaka Nakajima,Koki Shin,Kuniya Koizumi,Maki Saneshige,Makio Sekine,Makoto Yaida,Mari Kiuchi,Mari Mugishima,Mari Osawa,Masae Banno,Masahiro Yamamoto,Masatake Hiratsuka,Masumi Hosoya,Michika Atsuta,Mitsutoshi Kato,Miwa Morita,Munehiro Miyamae,Mutsumi Iijima,Naomi Okuyama,Nobuo Hisano,Norihiro Tsuchiya,Rie Wada,Ryuji Momose,Sachiko Otake,Satoko Maruyama,Satoru Takada,Shigeki Dan,Shigeki Nishizawa,Shigeo Yamashita,Shingo Saneshige,Shinichi Teno,Shinji Tsuruta,Shinobu Kumakura,Sumiko Kijima,Takashi Kondo,Takeo Onishi,Taku Kudo,Tatsushi Sugiura,Toshihiko Ishiguro,Yasue Suzuki,Yasuhiro Tomita,Yasuko Takano,Yoshihisa Akimoto,Yoshiko Odanaka,Yoshimasa Tasaka,Yoshitaka Aiso,Yukiko Inoue,Yukinobu Kobayashi
DOI: https://doi.org/10.1007/s13340-017-0330-2
2017-07-28
Abstract:Purpose: To determine the efficacy and safety of sitagliptin when used with some therapeutic drugs to treat elderly patients. Methods: Sitagliptin (50 mg/day) was added to the pre-existing therapy for type 2 diabetes. Changes in the glycated hemoglobin (HbA1c) level after 3 months of treatment were compared with the baseline, and exploratory analysis was performed. These analyses were conducted as subanalyses of the JAMP study, which was an open-label observational study. Results: For patients who were ≥65 years of age, the change in HbA1c level from baseline ranged from -0.50 to -0.87% at 3 months after starting treatment. There was no significant difference in the change in HbA1c level between the patients treated with different concomitant drugs. No significant difference in HbA1c variations at 3 and 12 months from baseline was noted among the three age groups (≥75, 65-74, and <65 years). Multiple regression analysis was performed, and it revealed that patients with higher HbA1c levels at baseline were likely to show decreased HbA1c levels, while those with higher triglyceride (TG) levels were unlikely to show decreased HbA1c levels. Conclusion: Sitagliptin has the potential to both improve glycemic control and prevent hypoglycemia, and can be considered a potent alternative drug.